ALK’s Acarizax approved for allergic rhinitis in Europe

ALK has announced that its house dust mite (HDM) sublingual allergy immunotherapy tablet (SLIT) Acarizax has been approved in Europe in a new indication.

The expanded approval covers patients aged 12 to 17 and will allow the therapy to be used in the treatment of adolescent patients with HDM-induced allergic rhinitis. This decision was based on positive data from clinical trials conducted in Japan and North America.

These results confirmed the favourable efficacy, safety and tolerability profile of the tablet in this indication, with the findings shown to be in line with previous studies in adults.

Acarizax first gained European approval for use in adults in 2015, when it also became the first SLIT product to be approved for use in allergic asthma.

Henrik Jacobi, ALK's executive vice-president for research and development, said: "For patients, it means there can now be an earlier intervention to treat a condition that has far-reaching consequences for teenagers whose sleep, education and social lives are blighted by house dust mite allergy."

To date, Acarizax has been approved in 17 countries worldwide and has been launched in nine.

With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.